Regulatory delays at Bengaluru and MDI facilities
US FDA issued Form 483 observations at Virgonagar (Bengaluru) and MDI facilities; official classification awaited, potentially delaying product approvals.
CIPLA / Q3-FY25 / risks
Keep the risk register visible.
Cipla · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
Lanreotide supply disruption recovery timeline
Lanreotide supply issues impacted US revenue; management expects normalization by end of Q4, but full capacity recovery may extend into Q1 FY26.
US tariff policy uncertainty
Potential US tariffs on pharmaceutical imports could impact margins; management noted de-risking via US facilities but awaits policy clarity.
Generic Revlimid revenue decline
Revlimid revenue is flat sequentially and expected to decline as competition increases; new launches may only partially offset the reduction.